Skip to main content
Clinical Trials/NCT06615713
NCT06615713
Completed
Not Applicable

A Prospective Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation (SURE) Using the CVAC® Set

Calyxo, Inc.2 sites in 1 country30 target enrollmentSeptember 5, 2024

Overview

Phase
Not Applicable
Intervention
Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System
Conditions
Renal Stones
Sponsor
Calyxo, Inc.
Enrollment
30
Locations
2
Primary Endpoint
Stone Clearance
Status
Completed
Last Updated
4 days ago

Overview

Brief Summary

The purpose of the study is to assess safety and efficacy of a novel steerable ureteral catheter system, the CVAC System for the treatment of urinary stones.

Registry
clinicaltrials.gov
Start Date
September 5, 2024
End Date
January 31, 2025
Last Updated
4 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Calyxo, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Candidate for ureteroscopy with laser lithotripsy;
  • Be willing and able to return for and respond to all study-related follow up procedures; and,
  • Have been informed of the nature of the study and have agreed to the IRB approved informed consent form (ICF).

Exclusion Criteria

  • Significant morbidities;
  • Unable to meet the treatment and follow up protocol requirements; and,
  • Ureteral or kidney abnormalities.

Arms & Interventions

Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System

The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).

Intervention: Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System

Outcomes

Primary Outcomes

Stone Clearance

Time Frame: Day 1 and Day 30

The stone clearance at Post-Op Day 1 (POD1) and Post-Op Day 30 (POD30) on non-contrast CT (NCCT)

Stone Clearance (% Reduction in Stone Volume)

Time Frame: 30 Days

The percent reduction (\[Baseline stone volume- 30-Day stone volume\] / Baseline stone volume) in stone volume following intervention, observed on non-contrast CT (NCCT) (2.0mm slice thickness). A positive result indicates a decrease in stone volume removed during the procedure; a negative value indicates an increase in stone volume following the procedure.

Residual Stone Volume (RSV)

Time Frame: 30 Days

A continuous quantitative measure of remaining stone volume following intervention, observed on non-contrast CT (NCCT) (2.0mm slice thickness).

Stone Free Rate (SFR) - Zero Fragments

Time Frame: 30 Days

Where stone free status is defined as zero residual fragments at 30 days observed on non-contrast CT (NCCT) (2.0mm slice thickness). SFR is calculated by determining the number of kidneys in each treatment arm with a stone free status of zero fragments and dividing that by the total number of kidneys treated in the respective treatment arm.

Study Sites (2)

Loading locations...

Similar Trials

Related News